\
&
Contact us
\
&
Contact us
Published on | 3 months ago
Programmes Security Digital, Industry & SpaceThe call is open to applications from academic institutions, innovation and technological centres and SMEs.
The objective is to select the most innovative solution, which will be integrated into the GOBEYOND MR-IEWS (Multi-Risk Impact-based Early Warning System).
The proposed solution should provide algorithms or developments to complement and improve the proposed MR-IEWS, ultimately boosting the innovation capacity of GOBEYOND’s advancements in decision-supporting tools for geo and weather hazards.
What is the prize?
The winning proposal will receive €50,000.
Opening date: 09 December 2024
Deadline: 31 January 2025 - 17:00 (CET)
For further information about the GOBEYOND project and to submit a project proposal, please visit the following website: https://gobeyond-project.eu/
Email address for further information: innovation_gobeyond@crahi.upc.edu
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI, data & cloud Advanced Digital Skills Deployment: Best use of technologies
The upcoming calls from the Digital Europe Main Work Programme have been published on the Funding & Tenders Portal of the European Commission. The following 10 call topics are expected to open for submission on 15 April 2025, deadline to submit proposals will be 2 September 2025: AI, data & cloud Apply AI: GenAI for the public ad... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
